Acrux Ltd - Company Profile
Powered by 
All the sales intelligence you need on Acrux Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Acrux Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Acrux Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Acrux Ltd (Acrux) is a speciality pharmaceutical company. It specializes in developing and commercializing generic topical prescription products. The company’s product portfolio includes Dapsone 5% gel, approved by the FDA for acne vulgaris and launched in the US under a license with TruPharma, and Lidocaine and Prilocaine 2.5%/2.5% licensed to Padagis. The company also developed Lenzetto, a transdermal estradiol spray for menopause-related hot flushes, licensed to Gedeon Richter in Europe, and Evamist, another estradiol spray licensed to Padagis. Acrux’s pipeline features Efinaconazole 10% solution, Dapsone 7.5% gel, Acyclovir 5% cream, and Nitroglycerin 0.4% ointment. Acrux is headquartered in West Melbourne, Victoria, Australia.
Headquarters
Australia
Address
103-113 Stanley St, West Melbourne, Victoria, 3003
Website
www.acrux.com.au
Telephone
61 3 83790100
No of Employees
43
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ACR (ASX)
Revenue (2025)
$3.0M
-44.1%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-2.5%
(2025 vs 2024)
Market Cap*
$3.5M
Net Profit Margin (2025)
XYZ
-83.3%
(2025 vs 2024)
* As of and is in US$
Acrux Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Dapsone 5%, Gel |
| Dapsone 7.5%, Gel |
| Nitroglycerine 0.4% Ointment |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In July, the company signed a sales, marketing, distribution and license agreement with Servacure Trading W.L.L. for Dapsone 5%, Gel for Saudi Arabia. |
| 2025 | New Products/Services | In May, the company launched Dapsone 7.5% is a generic version of Aczone Gel, 7.5%. |
| 2025 | New Products/Services | In January, the company launched 90grams pack size Dapsone 5%, Gel which treats acne vulgaris. |
Competitor Comparison
| Key Parameters | Acrux Ltd | Pfizer Inc | Glenmark Pharmaceuticals Ltd | Synthesis Med Chem Pty Ltd |
|---|---|---|---|---|
| Headquarters | Australia | United States of America | India | Australia |
| City | Melbourne | New York City | Mumbai | - |
| State/Province | Victoria | New York | Maharashtra | Victoria |
| No. of Employees | 43 | 81,000 | 13,477 | - |
| Entity Type | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John Warmbrunn | Chief Executive Officer; Managing Director | Executive Board | 2025 | - |
| Joanna Johnson | Chief Financial Officer; Secretary | Senior Management | 2021 | - |
| Ross Dobinson | Chairman | Non Executive Board | 1998 | - |
| Mark Hyman | Director - Project and Technical Development | Senior Management | 2020 | - |
| Felicia Colagrande | Director - Product Development and Technical Affairs | Senior Management | 2015 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer